Scientific articles

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. Atreya et al. J Crohns Colitis. 2016 Nov;10(11):1294-1302
Click for article

Treatment of ulcerative colitis patients by local application of the Toll like Receptor-9 agonist DIMS0150. Löfberg et al. Gastrointest Dig Syst. 2014, 4:6.
Click for article

Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors. Admyre et al. Immunology 2014, 144:206
Click for article

Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. Kuznetsov et al. BMC Gastroenterology 2014, 14:79.
Click for article

Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity Musch et al. Inflamm Bowel Dis. 2012 May 17.
Click for article

Neither Hide Nor Hair: The Difficulty of Identifying Useful Disease Biomarkers Editorial Gastroenterology (2008); 134:2164-68
Click for article

Multigene Analysis Can Discriminate Between Ulcerative Colitis, Crohn’s Disease, and Irritable Bowel Syndrome von Stein et al. Gastroenterology (2008); 134:1869-81
Click for article

The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis Kuznetsov et al. Oncogene (2005) 24, 3216-3222.
Click for article

Inflammatory bowel disease classification through multigene analysis: fact or fiction? Expert Rev. Mol. Diagn. 9(1), 7-10 (2009)
Click for article